| Abstrakt: |
A recent study conducted at Ohio State University aimed to measure the quality of life (QOL) and real-time patient experience during neoadjuvant therapy (NT) for gastrointestinal (GI) cancers. The study involved 104 patients who used a customized smartphone application to track their QOL and symptoms throughout the therapy. The results showed that overall QOL scores did not change during NT, although patients reported symptoms such as fatigue, insomnia, and anxiety. The study concluded that while patient symptom burden remained high, QOL was maintained during NT for localized GI cancers. [Extracted from the article] |
